Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis

被引:255
|
作者
Srivastava, Rajneesh [1 ]
Aslam, Muhammad [1 ]
Kalluri, Sudhakar Reddy [1 ]
Schirmer, Lucas [1 ]
Buck, Dorothea [1 ]
Tackenberg, Bjoern [2 ]
Rothhammer, Veit [1 ]
Chan, Andrew [3 ]
Gold, Ralf [3 ]
Berthele, Achim [1 ]
Bennett, Jeffrey L. [4 ,5 ]
Korn, Thomas [1 ]
Hemmer, Bernhard [1 ]
机构
[1] Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, D-81675 Munich, Germany
[2] Univ Marburg, Dept Neurol, Marburg, Germany
[3] Ruhr Univ Bochum, Dept Neurol, Bochum, Germany
[4] Univ Colorado, Dept Neurol, Denver, CO 80202 USA
[5] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA
关键词
RECTIFYING K+ CHANNEL; NEUROMYELITIS-OPTICA; SENSORINEURAL DEAFNESS; HETEROGENEITY; EXPRESSION; MUTATIONS; LESIONS; KCNJ10; IDENTIFICATION; DEMYELINATION;
D O I
10.1056/NEJMoa1110740
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. Many findings suggest that the disease has an autoimmune pathogenesis; the target of the immune response is not yet known. METHODS We screened serum IgG from persons with multiple sclerosis to identify antibodies that are capable of binding to brain tissue and observed specific binding of IgG to glial cells in a subgroup of patients. Using a proteomic approach focusing on membrane proteins, we identified the ATP-sensitive inward rectifying potassium channel KIR4.1 as the target of the IgG antibodies. We used a multifaceted validation strategy to confirm KIR4.1 as a target of the autoantibody response in multiple sclerosis and to show its potential pathogenicity in vivo. RESULTS Serum levels of antibodies to KIR4.1 were higher in persons with multiple sclerosis than in persons with other neurologic diseases and healthy donors (P<0.001 for both comparisons). We replicated this finding in two independent groups of persons with multiple sclerosis or other neurologic diseases (P<0.001 for both comparisons). Analysis of the combined data sets indicated the presence of serum antibodies to KIR4.1 in 186 of 397 persons with multiple sclerosis (46.9%), in 3 of 329 persons with other neurologic diseases (0.9%), and in none of the 59 healthy donors. These antibodies bound to the first extracellular loop of KIR4.1. Injection of KIR4.1 serum IgG into the cisternae magnae of mice led to a profound loss of KIR4.1 expression, altered expression of glial fibrillary acidic protein in astrocytes, and activation of the complement cascade at sites of KIR4.1 expression in the cerebellum. CONCLUSIONS KIR4.1 is a target of the autoantibody response in a subgroup of persons with multiple sclerosis. (Funded by the German Ministry for Education and Research and Deutsche Forschungsgemeinschaft.)
引用
收藏
页码:115 / 123
页数:9
相关论文
共 50 条
  • [41] The role of glial-specific Kir4.1 in normal and pathological states of the CNS
    Nwaobi, Sinifunanya E.
    Cuddapah, Vishnu A.
    Patterson, Kelsey C.
    Randolph, Anita C.
    Olsen, Michelle L.
    ACTA NEUROPATHOLOGICA, 2016, 132 (01) : 1 - 21
  • [42] Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO
    Higuchi, Osamu
    Nakane, Shunya
    Sakai, Waka
    Maeda, Yasuhiro
    Niino, Masaaki
    Takahashi, Toshiyuki
    Fukazawa, Toshiyuki
    Kikuchi, Seiji
    Fujihara, Kazuo
    Matsuo, Hidenori
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2016, 3 (05):
  • [43] In vitroandin silicocharacterization of the inhibition of Kir4.1 channels by aminoglycoside antibiotics
    Moran-Zendejas, Rita
    Delgado-Ramirez, Mayra
    Xu, Jie
    Valdes-Abadia, Belkis
    Arechiga-Figueroa, Ivan A.
    Cui, Meng
    Rodriguez-Menchaca, Aldo A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (19) : 4548 - 4560
  • [44] VU6036720: The First Potent and Selective In Vitro Inhibitor of Heteromeric Kir4.1/5.1 Inward Rectifier Potassium Channels
    McClenahan, Samantha J.
    Kent, Caitlin N.
    V. Kharade, Sujay
    Isaeva, Elena
    Williams, Jade C.
    Han, Changho
    Terker, Andrew
    Gresham, Robert
    Lazarenko, Roman M.
    Days, Emily L.
    Romaine, Ian M.
    Bauer, Joshua A.
    Boutaud, Olivier
    Sulikowski, Gary A.
    Harris, Raymond
    Weaver, C. David
    Staruschenko, Alexander
    Lindsley, Craig W.
    Denton, Jerod S.
    MOLECULAR PHARMACOLOGY, 2022, 101 (05) : 357 - 370
  • [45] Development and Validation of Fluorescence-Based and Automated Patch Clamp-Based Functional Assays for the Inward Rectifier Potassium Channel Kir4.1
    Raphemot, Rene
    Kadakia, Rishin J.
    Olsen, Michelle L.
    Banerjee, Sreedatta
    Days, Emily
    Smith, Stephen S.
    Weaver, C. David
    Denton, Jerod S.
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2013, 11 (9-10) : 532 - 543
  • [46] Inwardly rectifying K+ channels 4.1 and 5.1 (Kir4.1/Kir5.1) in the renal distal nephron
    Wang, Wen-Hui
    Lin, Dao-Hong
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2022, 323 (02): : C277 - C288
  • [47] Kir4.1 is coexpressed with stemness markers in activated astrocytes in the injured brain and a Kir4.1 inhibitor BaCl2 negatively regulates neurosphere formation in culture
    Kwon, Jae-Kyung
    Choi, Dong-Joo
    Yang, Haijie
    Ko, Dong Wan
    Jou, Ilo
    Park, Sang Myun
    Joe, Eun-Hye
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2021, 25 (06) : 565 - 574
  • [48] Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity
    Imamura, Michie
    Higuchi, Osamu
    Maeda, Yasuhiro
    Mukaino, Akihiro
    Ueda, Mitsuharu
    Matsuo, Hidenori
    Nakane, Shunya
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (24) : 1 - 12
  • [49] Expressional analysis of the astrocytic Kir4.1 channel in a pilocarpine-induced temporal lobe epilepsy model
    Nagao, Yuki
    Harada, Yuya
    Mukai, Takahiro
    Shimizu, Saki
    Okuda, Aoi
    Fujimoto, Megumi
    Ono, Asuka
    Sakagami, Yoshihisa
    Ohno, Yukihiro
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2013, 7
  • [50] Heterozygous KCNJ10 Variants Affecting Kir4.1 Channel Cause Paroxysmal Kinesigenic Dyskinesia
    Huang, Xiaojun
    Fu, Xin
    Wu, Jingying
    Cheng, Xin
    Hong, Xiaoqi
    Li, Ziyi
    Zheng, Lan
    Liu, Qing
    Chen, Shendi
    Tang, Beisha
    Zhao, Yuwu
    Liu, Xiaorong
    Li, Xunhua
    Liu, Xiaoli
    Zhou, Zaiwei
    Wu, Li
    Fang, Kan
    Zhong, Ping
    Zhang, Mei
    Luan, Xinghua
    Tian, Wotu
    Tong, Xiaoping
    Cao, Li
    MOVEMENT DISORDERS, 2024, 39 (12) : 2199 - 2210